In the present study, we found that with the prolongation of trastuzumab-based neoadjuvant therapy and adjuvant therapy time, miR-497 was gradually decreased, FGF-23 was gradually increased, and the miR-497/FGF-23 axis was gradually reduced in HER2-positive breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.